MYIA
KRYS icon

Mount Yale Investment Advisors’s Krystal Biotech KRYS Stock Holding History

Mount Yale Investment Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$292K Buy
+1,130
New +$301K 0.01% 907
2025
Q3 		– Sell
-1,251
Closed -$172K – 1173
2025
Q2 		$172K Buy
1,251
+12
+1% +$1.76K 0.01% 564
2025
Q1 		$223K Buy
+1,239
New +$208K 0.02% 496
2024
Q4 		– Sell
-1,027
Closed -$187K – 593
2024
Q3 		$187K Buy
+1,027
New +$198K 0.02% 530

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mount Yale Investment Advisors's KRYS Position: Q1 2026 in Review

Mount Yale Investment Advisors opened a new position in Krystal Biotech (KRYS) in Q1 2026: 1,130 shares worth $292K. The stake represents 0.01% of the portfolio and ranks #907 among its holdings. This is a return to the name: Mount Yale Investment Advisors previously reported a position in KRYS as recently as Q2 2025.

Mount Yale Investment Advisors first reported a position in KRYS in Q3 2024 and has held it in 4 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Mount Yale Investment Advisors held 1,130 shares of Krystal Biotech worth $292K as of Q1 2026.
  • Krystal Biotech was a new Mount Yale Investment Advisors position in Q1 2026.
  • Krystal Biotech made up 0.01% of Mount Yale Investment Advisors's portfolio in Q1 2026, its #907 holding.
  • Mount Yale Investment Advisors first reported a position in Krystal Biotech in Q3 2024 and has held it in 4 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.